# A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India

> **NCT05219253** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 288 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** HZ/su
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05219253
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-02
- **Primary completion:** 2022-10-11
- **Final completion:** 2022-12-12
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05219253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05219253, "A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05219253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*